Levodopa News and Research

RSS

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Low-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease (PD) - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year. The third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.

28 Jul 2015

Severe dyskinesias rare in community Parkinson’s cohort

Motor fluctuations and dyskinesias affect about a third of community-based patients with Parkinson’s disease, but dyskinesias are rarely severe enough to warrant a change of treatment, report researchers.

15 Jul 2015

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company's Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease (PD).

30 Jun 2015

Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Health Canada is informing Canadians that eight unauthorized health products (listed in the table below) were seized from Better Bodies Supplements, 118 Main Street North, in Airdrie, Alta.

27 Jun 2015

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

BIAL is presenting 11 research posters at the 19th International Congress of Parkinson's Disease and Movement Disorders (June 14–15, San Diego, CA). These evaluate the safety and efficacy of opicapone (BIA 9-1067), a novel once-daily catechol-O-methyltransferase (COMT) inhibitor for use as adjunctive therapy in levodopa-treated Parkinson’s disease patients with end of dose motor fluctuations.

15 Jun 2015

Promising results for multi-source DBS in Parkinson’s disease

Deep-brain stimulation targeting the subthalamic nucleus with a multiple-source constant-current device effectively suppresses motor symptoms in patients with advanced Parkinson’s disease, report researchers.

12 Jun 2015

New treatment shows promise in easing symptoms of Parkinson's disease

To date, a cure for Parkinson's disease remains elusive for the more than 50,000 Americans diagnosed yearly, despite decades of intensive study. But a newly approved treatment that might help ease the symptoms of Parkinson's has shown remarkable promise.

22 Apr 2015

Bilirubin levels raised in newly diagnosed Parkinson’s disease

Bilirubin levels are upregulated in patients with early Parkinson’s disease and are associated with disease progression at 2 years, a study shows.

7 Apr 2015

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1.

13 Mar 2015

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel.

4 Mar 2015

Perceived cost affects placebo response in Parkinson’s disease

Patients with Parkinson’s disease may gain a greater benefit from a placebo treatment if they believe it to be expensive, research suggests.

27 Feb 2015

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

Although levodopa remains the "gold standard" to effectively control motor deficits in the treatment of early stage Parkinson's disease (PD), it loses effectiveness as the disease progresses. After four to six years of treatment with oral medications for Parkinson's disease, about 40% of patients experience lack of muscle control (dyskinesias), end-of-dose wearing off, and fluctuations in "On/Off" states.

27 Feb 2015

UC San Diego Health System's Movement Disorder Center joins NPF Center of Excellence network

The Movement Disorder Center at UC San Diego Health System has been designated the 41st Center of Excellence in the National Parkinson Foundation's global network. This designation is the highest recognition offered by NPF to a Parkinson's specialty clinic. It represents the consensus of leaders in the field that the UC San Diego program is among the world's leading centers for Parkinson's research, outreach and care.

27 Feb 2015

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1.

13 Feb 2015

Researchers close to novel therapy to treat levodopa-induced dyskinesia

Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson's disease. Now, however, researchers at Karolinska Institutet and Lund University in Sweden seem to be close to a novel therapy to this distressing side effect.

11 Feb 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

29 Dec 2014

Non-ergot derived dopamine agonists may be safe for the heart

Non-ergot derived dopamine agonists used to treat Parkinson's disease may be safe for the heart, according to preliminary research presented at EuroEcho-Imaging 2014 by Dr Hilal Erken Pamukcu, cardiologist at Ankara Diskapi Education and Research Hospital in Turkey.

4 Dec 2014

Impax announces submission of EMA Marketing Authorization Application for IPX066

Impax Laboratories (Netherlands) B.V., a wholly owned subsidiary of Impax Laboratories, Inc. today announced that it has submitted a Marketing Authorization Application for IPX066 to the European Medicines Agency. IPX066 is an investigational extended-release capsule formulation of carbidopa-levodopa for the treatment of idiopathic Parkinson's disease.

6 Nov 2014

Levodopa dose linked to malnutrition risk in Parkinson’s disease

The malnutrition often seen in patients with Parkinson’s disease could be partly an effect of levodopa medication, research suggests.

22 Oct 2014

Levodopa News and Research

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Severe dyskinesias rare in community Parkinson’s cohort

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

Promising results for multi-source DBS in Parkinson’s disease

New treatment shows promise in easing symptoms of Parkinson's disease

Bilirubin levels raised in newly diagnosed Parkinson’s disease

Creatine monohydrate disappoints in Parkinson’s disease

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Perceived cost affects placebo response in Parkinson’s disease

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

UC San Diego Health System's Movement Disorder Center joins NPF Center of Excellence network

Creatine monohydrate disappoints in Parkinson’s disease

Researchers close to novel therapy to treat levodopa-induced dyskinesia

FDA approves RYTARY for Parkinson's disease treatment

Newron, Zambon announce re-submission of safinamide NDA to FDA

Non-ergot derived dopamine agonists may be safe for the heart

Impax announces submission of EMA Marketing Authorization Application for IPX066

Levodopa dose linked to malnutrition risk in Parkinson’s disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News